Nephrol Dial Transplant (2002) 17: 66-70
© 2002 European Renal Association-European Dialysis and Transplant Association
Optimizing the use of erythropoietic agents – pharmacokinetic and pharmacodynamic considerations
Department of Renal Medicine, King's College Hospital, London, UK
Abstract
Erythropoietic agents have transformed the management of renal anaemia. Two forms of recombinant human erythropoietin (rHuEPO) have been available since the early 1990s, and more recently, a second-generation erythropoietic agent, darbepoetin alfa, has been granted a licence for treating this condition. The endogenous erythropoietin molecule may contain anything from 4 to 14 sialic acid residues. The various isoforms have different biological potencies in vivo owing to their different metabolic clearance rates. However, there is a continuing debate about those organs potentially involved in the metabolism of the erythropoietin molecule; the kidneys, liver, and bone marrow have all been suggested as possible participants. Darbepoetin alfa contains two extra N-linked glycosylation consensus sequences increasing the potential maximum number of sialic acid residues from 14 up to 22. In vitro, the affinity of darbepoetin alfa for the erythropoietin receptor is less than for the natural ligand, but this is more than compensated for by the increased potency in vivo. One of the most important factors determining the biological activity of erythropoiesis-stimulating agents is the length of time that the serum concentration of the protein remains above the threshold necessary for erythropoiesis. The pharmacokinetic profile of darbepoetin alfa is distinct from that of rHuEPO, the major difference being the much longer elimination half-life and slower clearance in vivo of darbepoetin alfa leading to prolonged erythropoietic activity. Stimulation of erythropoiesis depends both on an ambient circulating level of erythropoietin and on the mechanisms governing the interaction of the hormone with its receptor. Our knowledge regarding the latter is limited and it is difficult to predict the optimum frequency of administration for an erythropoietic agent. In general, rHuEPO is given two or three times weekly. A small number of studies have supported the once-weekly use of rHuEPO. All clinical trials so far conducted on darbepoetin alfa have demonstrated success with once-weekly and once every other week dosing.
Keywords: anaemia; chronic kidney disease; darbepoetin alfa; erythropoietin; pharmacodynamics; pharmacokinetics
Notes
Correspondence and offprint requests to: Dr Iain C. Macdougall, Consultant Nephrologist, Renal Unit, King's College Hospital, East Dulwich Grove, London SE22 8PT, UK. Email: icm\|[hyphen]\|kru{at}globalnet.co.uk
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  X. Chen, Y D. Liu, and G. C Flynn The effect of Fc glycan forms on human IgG2 antibody clearance in humans Glycobiology, March 1, 2009; 19(3): 240 - 249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. L. Metzger, K. E. Francis, and S. A. Voils A Comparative Review of Erythropoiesis Stimulating Agents Journal of Pharmacy Practice, December 1, 2008; 21(6): 424 - 430. [Abstract] [PDF]
|
|
|
|
|
|
E. Hassan Anemia in the Critically Ill Patient Journal of Pharmacy Practice, December 1, 2008; 21(6): 405 - 410. [Abstract] [PDF]
|
|
|
|
 |
|
 R. G. Walker Erythropoietin Stimulating Agents and Epoetin Alfa Revisited: What's Really Relevant? Clin. J. Am. Soc. Nephrol., July 1, 2008; 3(4): 935 - 937. [Full Text] [PDF]
|
|
|
|
 |
|
 I. C. Macdougall, D. Padhi, and G. Jang Pharmacology of darbepoetin alfa Nephrol. Dial. Transplant., June 1, 2007; 22(suppl_4): iv2 - iv9. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Barany and H.-J. Muller Maintaining control over haemoglobin levels: optimizing the management of anaemia in chronic kidney disease Nephrol. Dial. Transplant., June 1, 2007; 22(suppl_4): iv10 - iv18. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Carrera, A. Disney, and M. Molina Extended dosing intervals with erythropoiesis-stimulating agents in chronic kidney disease: a review of clinical data Nephrol. Dial. Transplant., June 1, 2007; 22(suppl_4): iv19 - iv30. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. W. Gross and H. F. Lodish Cellular Trafficking and Degradation of Erythropoietin and Novel Erythropoiesis Stimulating Protein (NESP) J. Biol. Chem., January 27, 2006; 281(4): 2024 - 2032. [Abstract] [Full Text] [PDF]
|
|